Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification

被引:19
|
作者
Pu, Jiali [1 ,2 ]
Frescas, David [1 ]
Zhang, Baorong [2 ]
Feng, Jian [1 ,3 ]
机构
[1] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 2, Dept Neurol, Hangzhou 310009, Zhejiang, Peoples R China
[3] Vet Affairs Western New York Healthcare Syst, Buffalo, NY 14215 USA
关键词
TALENs; CRISPR/Cas9; gene editing; disease modeling; gene therapy; EMBRYONIC STEM-CELLS; STRAND BREAK REPAIR; HIGH-EFFICIENCY; HOMOLOGOUS RECOMBINATION; GENOME MODIFICATION; DROSOPHILA GENOME; CAS9; NUCLEASE; ZINC-FINGER; RNA; GENERATION;
D O I
10.1177/1535370215584932
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The capability to modify the genome precisely and efficiently offers an extremely useful tool for biomedical research. Recent developments in genome editing technologies such as transcription activator-like effector nuclease and the clustered regularly interspaced short palindromic repeats system have made genome modification available for a number of organisms with relative ease. Here, we introduce these genome editing techniques, compare and contrast each technical approach and discuss their potential to study the underlying mechanisms of human disease using patient-derived induced pluripotent stem cells.
引用
收藏
页码:1065 / 1070
页数:6
相关论文
共 50 条
  • [31] The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice
    Zhanhui Ou
    Xiaohua Niu
    Wenyin He
    Yuchang Chen
    Bing Song
    Yexing Xian
    Di Fan
    Daolin Tang
    Xiaofang Sun
    Scientific Reports, 6
  • [32] Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
    LaFountaine, Justin S.
    Fathe, Kristin
    Smyth, Hugh D. C.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 494 (01) : 180 - 194
  • [33] Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
    Gori, Jennifer L.
    Hsu, Patrick D.
    Maeder, Morgan L.
    Shen, Shen
    Welstead, G. Grant
    Bumcrot, David
    HUMAN GENE THERAPY, 2015, 26 (07) : 443 - 451
  • [34] The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice
    Ou, Zhanhui
    Niu, Xiaohua
    He, Wenyin
    Chen, Yuchang
    Song, Bing
    Xian, Yexing
    Fan, Di
    Tang, Daolin
    Sun, Xiaofang
    SCIENTIFIC REPORTS, 2016, 6
  • [35] Targeting SIVmac239 genome with CRISPR/Cas9 gene editing technology
    Mancuso, Pietro
    Young, Won-Bin
    Nawrat, Dominika
    Burdo, Tricia H.
    MacLean, Andrew
    Kaminski, Rafal
    Khalili, Kamel
    JOURNAL OF NEUROVIROLOGY, 2018, 24 : S52 - S52
  • [36] High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9
    Varshney, Gaurav K.
    Pei, Wuhong
    LaFave, Matthew C.
    Idol, Jennifer
    Xu, Lisha
    Gallardo, Viviana
    Carrington, Blake
    Bishop, Kevin
    Jones, MaryPat
    Li, Mingyu
    Harper, Ursula
    Huang, Sunny C.
    Prakash, Anupam
    Chen, Wenbiao
    Sood, Raman
    Ledin, Johan
    Burgess, Shawn M.
    GENOME RESEARCH, 2015, 25 (07) : 1030 - 1042
  • [37] Targeting the MALAT1 gene with the CRISPR/Cas9 technique in prostate cancer
    Soraya Ahmadi-Balootaki
    Abbas Doosti
    Mojtaba Jafarinia
    Hamed Reza Goodarzi
    Genes and Environment, 44
  • [38] Gene targeting of dikaryotic Pleurotus ostreatus nuclei using the CRISPR/Cas9 system
    Yamasaki, Fuga
    Nakazawa, Takehito
    Oh, Minji
    Bao, Dapeng
    Kawauchi, Moriyuki
    Sakamoto, Masahiro
    Honda, Yoichi
    FEMS MICROBIOLOGY LETTERS, 2022, 369 (01)
  • [39] Targeting the MALAT1 gene with the CRISPR/Cas9 technique in prostate cancer
    Ahmadi-Balootaki, Soraya
    Doosti, Abbas
    Jafarinia, Mojtaba
    Goodarzi, Hamed Reza
    GENES AND ENVIRONMENT, 2022, 44 (01)
  • [40] Targeting SIVmac239 genome with CRISPR/Cas9 gene editing technology
    Mancuso, Pietro
    Young, Won-Bin
    Nawrat, Dominika
    Burdo, Tricia H.
    MacLean, Andrew
    Kaminski, Rafal
    Khalili, Kamel
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2018, 13 : S52 - S52